<DOC>
	<DOC>NCT02612610</DOC>
	<brief_summary>This is a 12-week, randomized, parallel, double-blind, placebo-controlled study of AF-219 in subjects with refractory chronic cough.</brief_summary>
	<brief_title>A 12-Week Study in Subjects With Refractory Chronic Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>Women and Men between 18 and 80 years of age inclusive Have refractory chronic cough Women of childbearing potential must use 2 forms of acceptable birth control Have provided written informed consent. Are willing and able to comply with all aspects of the protocol Current smoker FEV1/FVC &lt; 60% History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit History of opioid use within 1 week of the Baseline Visit Body mass index (BMI) &lt;18 kg/m2 or â‰¥ 40 kg/m2 History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with &lt;3 excised basal cell carcinomas) Screening systolic blood pressure (SBP) &gt;160 mm Hg or a diastolic blood pressure (DBP) &gt;90 mm Hg Clinically significant abnormal electrocardiogram (ECG) at Screening Significantly abnormal laboratory tests at Screening Pregnant or Breastfeeding Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the subject inappropriate for entry into this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>